Drug Trial Radar · NCT07936266
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Mar 31, 2027
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Sunil G. IyerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.
Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
AsciminibDrug
Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket), and is an approved TKI in newly-diagnosed and previously-treated chronic myeloid leukemia (CML). It is a non-chemotherapeutic, oral agent which specifically and potently targets the mutant Philadelphia chromosome driven by t(9;22). Due to its novel mechanism of action as a STAMP, asciminib is active in the setting of mutations in the BCR-ABL ATP-binding pocket including the T315I gatekeeper mutations, which confers resistance to first- and second-generation tyrosine kinase inhibitors (TKIs). Asciminib has not yet been studied in Philadelphia-chromosome positive B-ALL.
Inotuzumab ozogamicinDrug
Inotuzumab ozogamicin (INO) is an antibody-drug conjugate which targets CD22, an antigen present in \>90% of B-ALL cases. INO is FDA approved and a standard-of-care treatment in relapsed/refractory B-ALL. The drug is approved and active in Ph-positive and -negative disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse eventsTime frame: 36 Months
- Maximum Tolerated Dose (MTD) of asciminibTime frame: 36 Months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida · Not yet recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Not yet recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
University of Washington Fred Hutchinson Comprehensive Cancer Center
Seattle, Washington · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.